• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Johns Hopkins Launches First Psilocybin Trial for Stroke Recovery

by Fred Pennic 06/04/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Johns Hopkins Launches First Psilocybin Trial for Stroke Recovery

What You Should Know: 

– Johns Hopkins University has signed an agreement with Rose Hill Life Sciences, a global leader in the research and intellectual property of premium psilocybin products to exclusively license intellectual property related to improving motor functions in patients with neurological injuries through the use of psychedelic therapy. 

– The collaboration aims to explore the potential of psilocybin to enhance recovery from conditions such as stroke.

Transforming Stroke Recovery Through Psilocybin-Enhanced Neuroplasticity

This Phase 1 trial investigates whether combining psilocybin with digitally enhanced physical therapy can reignite neuroplasticity and reopen recovery windows long after a stroke — a potential paradigm shift in how we treat long-term disability. The trial is led by renowned researchers Drs. Gül Dölen, Steve Zeiler, and John Krakauer at Johns Hopkins.

The licensed invention encompasses methods for improving motor function in individuals who have experienced an acute, subacute, or chronic central nervous system (CNS) injury, as well as for treating focal diaschisis (a sudden loss of function in a portion of the brain connected to a distant, damaged brain area) caused by such injuries. Experts involved in the development of this intellectual property believe that psilocybin-assisted therapy could offer a new paradigm for neurological rehabilitation, particularly for stroke survivors.

Gül Dölen, MD, PhD, Professor and Parson’s Endowed Chair of Neuroscience and Psychology at UC Berkeley and Adjunct Professor of Neuroscience and Neurology at Johns Hopkins University, added, “Psychedelics have shown remarkable potential to reopen critical periods — if harnessed correctly this reopened window of brain malleability, could revolutionize stroke rehabilitation. This license represents an exciting step toward understanding how psilocybin can rewire the brain, potentially leading to more effective and lasting recovery strategies for stroke survivors”.

Rose Hill’s Commitment to Advancing Psychedelic Medicine

Rose Hill Life Sciences, known as the world’s inaugural legal exporter of psilocybin, is dedicated to advancing scientific research and expanding the therapeutic applications of psilocybin. The company supports pioneering clinical research exploring psilocybin’s potential for treating mental health and neurological conditions through its integrated operations spanning Jamaica, the United States, and Canada, and via strategic partnerships with esteemed research institutions.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Psychedelic Healthcare

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |